Dewpoint Therapeutics kicks off with $60m financing
Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
IPO: Marinomed sets offer price
Marinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share.
Can machines learn to discover drugs?
Take the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is also asking what forms of artifical intelligence can be slotted in at what stages in the process. AI-powered drug repurposing has seen some candidates enter clinical stage testing, but its still unclear whether the technology is already powerful enough for de novo molecule discovery.
Novozymes partners with Carbios subsidiary Carbiolice
Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
Biomarker predicts response to TNF blockers
A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
The great green rush
Its the most commonly cultivated, trafficked and abused illicit drug worldwide, and theres still a lot of social stigma attached to the recreational use of pot. But its slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
UK launches new payment model for antimicrobials
In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
BioNtech swallows MAB Discovery antibody unit
Immunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discoverys antibody generation unit.
Clariant inks cellulosic biodiesel pact with ExxonMobil/REG
Swiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
IMI launches €80m call
The Innovative Medicines Initiative II has earmarked €80m for pre-competetive research improving the pharmaceutical industry’s productivity.